The most valuable skill in peptide medicine is not remembering a list of doses. It is learning how to think through a case when the evidence, regulatory context and individual patient factors do not fit neatly into a template.
The protocol-first problem
Peptide medicine is often presented online as a menu: match a concern to a compound, select a schedule and wait for an outcome. That approach may feel efficient, but it removes the clinical decisions that protect both patient and practitioner.
A protocol cannot establish a diagnosis, identify a contraindication, judge the quality of available evidence, verify the status and quality of a medicine, obtain meaningful consent or decide whether a treatment should be continued. Those responsibilities remain with the treating practitioner.
A seven-part clinical framework
1. Define the clinical problem
Begin with the patient’s actual problem—not with the intervention you hope to use. Clarify the indication, relevant diagnoses, baseline symptoms, previous treatment and the outcome that would represent meaningful improvement.
2. Assess the whole patient
History, examination, co-morbidities, current medication, reproductive considerations, expectations and capacity for follow-up all influence suitability. Baseline investigations should be selected because they answer a clinical question, not because they appear on a generic panel.
3. Appraise evidence and uncertainty
Biological plausibility is not the same as proven clinical benefit. Doctors should be able to explain what is known, what remains uncertain and how directly the available evidence applies to the proposed use. Emerging medicine demands curiosity and restraint at the same time.
4. Verify the regulatory and quality context
Practitioners must understand the current registration or authorisation status of the medicine they are considering, the lawful route by which it is supplied and the quality documentation relevant to that route. Where regulated access applies, the treating practitioner retains clinical responsibility.
5. Make consent genuinely informed
Consent is more than a signature. The discussion should address the proposed rationale, realistic potential benefit, uncertainty, material risk, alternatives, financial implications and the option of no treatment.
6. Build monitoring into the plan
Before treatment begins, define what will be monitored, when it will be reviewed and what would trigger adjustment, discontinuation or referral. A defensible plan includes both effectiveness and safety outcomes.
7. Document the reasoning
Good records should make the clinical logic visible: why the intervention was considered, what alternatives were discussed, what the patient understood, which follow-up was agreed and how subsequent decisions were reached.
What this changes in practice
A framework does not eliminate uncertainty. It helps doctors manage uncertainty consistently. It also makes it easier to recognise when a patient should not be treated, when more information is needed and when referral or an established alternative is the better decision.
This is the difference between collecting protocols and developing professional competence.
Dr Luhard’s approach to mentorship
At MedBase, Dr Luhard Jansen van Vuuren teaches peptide medicine as a clinical reasoning discipline. The goal is to help doctors connect assessment, evidence, responsible prescribing, consent, follow-up and real-world patient communication.
Small-group teaching allows uncertainty to be discussed openly. Doctors can test their reasoning, work through clinical scenarios and learn how an experienced clinician approaches the difficult questions that cannot be answered by a protocol sheet.
Frequently asked questions
Why is a peptide protocol alone not enough?
A protocol cannot replace diagnosis, patient selection, assessment of evidence and product status, informed consent, monitoring or the practitioner’s independent clinical judgement.
Who may attend MedBase peptide training?
The programme is intended for HPCSA-registered medical doctors and dentists. Registration status is verified before a booking is finalised.
When are the remaining 2026 MedBase peptide courses?
The remaining dates are 4 September and 23 October 2026, from 13:00 to 17:00 at MedBase Academy in Waterkloof, Pretoria.
Professional guidance
Practitioners should work with current professional and regulatory guidance, including the HPCSA ethical guidance, current CPD guidance and relevant SAHPRA guidance.
This article is professional education, not patient-specific medical advice. Practitioners remain responsible for independent judgement and compliance with current law, scope, evidence and regulatory requirements.